Mergers and Acquisitions (M&A) in the Diabetes Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Mergers and Acquisitions in the Diabetes Market include analysis by Geography, Mergers and Acquisitions, Partnerships, and Collaborations among diabetes drugs and devices companies.

Mergers and Acquisitions (M&A) in the Diabetes Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Mergers and Acquisitions in the diabetes market size

Mergers And Acquisitions In The Diabetes Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Market Size (2025) USD 88.89 Billion
Market Size (2030) USD 106.55 Billion
CAGR (2025 - 2030) 3.69 %
Fastest Growing Market North America
Largest Market North America

Major Players

Mergers And Acquisitions In The Diabetes Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Mergers And Acquisitions In The Diabetes Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Mergers and acquisitions in the diabetes market analysis

The Mergers And Acquisitions In The Diabetes Market size is estimated at USD 88.89 billion in 2025, and is expected to reach USD 106.55 billion by 2030, at a CAGR of 3.69% during the forecast period (2025-2030).

Diabetes is a chronic condition characterized by high blood glucose levels caused by the inability to produce or use insulin effectively. Diabetes treatment aims to maintain healthy blood glucose levels to prevent short- and long-term complications, such as cardiovascular disease, kidney disease, blindness, and lower limb amputation. Furthermore, patients attempting to control their blood glucose levels tightly to prevent the long-term complications associated with fluctuations in blood glucose levels are at greater risk for overcorrection and the resultant hypoglycemia. Achieving nominal results can be very difficult without diabetes care devices and medications.

Mergers and acquisitions help manufacturers to accomplish exponential, rather than just linear growth, and thereby continue to intrigue the interest of investors. In the Diabetes market, Mergers and acquisitions are critical tools for strategy implementation. Deal-making is critical for implementing game-changing strategic actions and building organizations ready to face future difficulties. However, diabetic businesses use mergers and acquisitions as a routine part of their business model to gain access to innovation, as well as to optimize manufacturing operations and prune business portfolios.

The key factors driving diabetes market mergers and acquisitions are strategic changes to achieve the segment's critical size requirement and large mergers that allow the bundling of subcritical businesses to build new platforms. The other driving force behind mergers and acquisitions is efficient capital allocation across the industry, which applies to R&D and manufacturing. The originators' large, complex organizations are unsuitable for fostering innovation. An ecosystem of venture capital and entrepreneurs has proven far more effective in identifying and allocating funds to early-stage biomedical research opportunities. Essentially, venture capitalists pre-fund diabetes drug companies' early-stage development.

Therefore, owing to the factors above, the studied market is anticipated to grow over the analysis period.

Mergers And Acquisitions In The Diabetes Industry Overview

Some prominent players in the market are Medtronic, Eli Lily, Sanofi, Dexcom, and Novo Nordisk, among others. Mergers and acquisitions between players in the recent past helped companies strengthen their market presence and develop capabilities that are novel to the companies. For instance, in July 2021, Eli Lily and Company announced the acquisition of Protomer Technologies Inc. to focus on advancing glucose-responsive insulins and accelerate the development of next-generation protein therapeutics.

Mergers And Acquisitions In The Diabetes Market Leaders

  1. Eli Lily and Company

  2. Sanofi Aventis

  3. Dexcom

  4. Novo Nordisk

  5. Medtronic

  6. *Disclaimer: Major Players sorted in no particular order
Mergers And Acquisitions In The Diabetes Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Mergers And Acquisitions In The Diabetes Market News

  • March 2023: Sanofi announced that it will pay USD 25 per share in cash or about USD 2.9 billion for Provention Bio; the deal is expected to close in the second quarter of 2023. The deal gives Sanofi access to Provention's approved immunotherapy Tzield, designed to stall the progression of type 1 diabetes.
  • February 2023: Insulet acquired assets related to Bigfoot Biomedical's pump-based automated insulin delivery (AID) technologies for USD 25 million. Insulet and Bigfoot offer two distinct forms of diabetes-management care: Insulet's Omnipod system that delivers insulin via a wearable, tubeless pump dubbed the Pod and a remote controller called the Personal Diabetes Manager (PDM). Bigfoot's Unity provides injection support technologies that leverage smartpen caps and provide dose suggestions to patients based on continuous glucose monitoring data and provider recommendations.

Mergers & Acquisitions in the Diabetes Market Report - Table of Contents

1. INTRODUCTION

2. RESEARCH METHODOLOGY

3. MARKET DYNAMICS

4. COMPETITIVE LANDSCAPE

  • 4.1 Company Profiles
    • 4.1.1 Diabetes Care Drugs Company Profiles
    • 4.1.1.1 Novo Nordisk
    • 4.1.1.2 Sanofi Aventis
    • 4.1.1.3 Eli Lily and Company
    • 4.1.1.4 AstraZeneca
    • 4.1.1.5 Boehringer Ingelheim
    • 4.1.1.6 Viatris Inc.
    • 4.1.1.7 Pfizer
    • 4.1.1.8 Merck & Co.
    • 4.1.1.9 Novartis AG
    • 4.1.1.10 Teva Pharmaceutical Industries Ltd.
    • 4.1.2 Diabetes Care Devices Company Profiles
    • 4.1.2.1 Abbott Diabetes Care
    • 4.1.2.2 F. Hoffmann-La Roche AG
    • 4.1.2.3 Dexcom
    • 4.1.2.4 Medtronic
    • 4.1.2.5 Becton Dickinson
    • 4.1.2.6 Ypsomed Holding AG
    • 4.1.2.7 Insulet Corporation
    • 4.1.2.8 Terumo
  • *List Not Exhaustive

5. MARKET SEGMENTATION

  • 5.1 Geography
  • 5.2 Merger, Acquisition, Partnership, and Collaboration

6. REGULATORY CHALLENGES

7. PATIENT EXPERIENCE GAP ASSESSMENT

8. MARKET OPPORTUNITIES AND FUTURE TRENDS

  • 8.1 Market Reaction and Future Growth in the Healthcare Industry
  • 8.2 Impact on HCPs - Prescription Pattern and Approach towards Products
  • 8.3 Product Impact and Value among Patients
  • 8.4 Effect of Merger and Acquisition Engagement on Companies
  • 8.5 Merger and Acquisition Outlook Survey Outcomes
**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Mergers And Acquisitions In The Diabetes Industry Segmentation

Mergers and acquisitions are business transactions in which the ownership of companies, business organizations, or their operating units are transferred to or consolidated with another company or business organization. The Mergers and Acquisitions in the Diabetes Market include analysis by Geography, Mergers and Acquisitions, Partnerships, and Collaborations among major drug and device companies. The report covers detailed company profiles of the companies that provide diabetes care drugs and devices, including business overviews, products and services, financials, contracts, mergers and acquisitions, joint ventures, collaborations, and other business agreements and strategies adopted by leading players in the market. The report covers all major mergers and acquisitions, partnerships, and collaborations in the diabetes care drugs and devices market.

Need A Different Region or Segment?
Customize Now

Mergers & Acquisitions in the Diabetes Market Research FAQs

How big is the Mergers And Acquisitions In The Diabetes Market?

The Mergers And Acquisitions In The Diabetes Market size is expected to reach USD 88.89 billion in 2025 and grow at a CAGR of 3.69% to reach USD 106.55 billion by 2030.

What is the current Mergers And Acquisitions In The Diabetes Market size?

In 2025, the Mergers And Acquisitions In The Diabetes Market size is expected to reach USD 88.89 billion.

Who are the key players in Mergers And Acquisitions In The Diabetes Market?

Eli Lily and Company, Sanofi Aventis, Dexcom, Novo Nordisk and Medtronic are the major companies operating in the Mergers And Acquisitions In The Diabetes Market.

Which is the fastest growing region in Mergers And Acquisitions In The Diabetes Market?

North America is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Mergers And Acquisitions In The Diabetes Market?

In 2025, the North America accounts for the largest market share in Mergers And Acquisitions In The Diabetes Market.

What years does this Mergers And Acquisitions In The Diabetes Market cover, and what was the market size in 2024?

In 2024, the Mergers And Acquisitions In The Diabetes Market size was estimated at USD 85.61 billion. The report covers the Mergers And Acquisitions In The Diabetes Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Mergers And Acquisitions In The Diabetes Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Mergers and Acquisitions in the Diabetes Industry Report

Statistics for the 2025 Mergers And Acquisitions In The Diabetes market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Mergers And Acquisitions In The Diabetes analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.